ГОСТ 32383—2013
[25] IPCS (1986). Principles and Methods for the Assessment of Neurotoxicity Associated with
Exposure to Chemicals. Environmental Health Criteria Document No. 60.
[26] Tupper. D.E.. Wallace, R.B. (1980). Utility of the Neurologic Examination in Rats. Acta Neurobiol.
Exp.. 40. 999-1003.
[27] Gad. S.C. (1982). A Neuromuscular Screen for Use in Industrial Toxicology. J. ToxicoI.Environ.
Health. 9. 691-704.
[28] Moser, V.C.. McDaniel. K.M., Phillips. P.M. (1991). Rat Strain and Stock Comparisons Using a
Functional Observational Battery: Baseline Values and Effects of Amitraz. Toxicol. Appl. Pharmacol.. 108,
267-283.
[29] Meyer O.A., Tilson H.A.. Byrd W.C., Riley M.T. (1979). A Method for the RoutineAssessment of
Fore- and Hind-timb Grip Strength of Rats and Mice. Neurobehav. Toxicol.. 1. 233-236. Draft consultant’s
proposal. V. 8. OECD TG 452 November. 2008, 14
[30] Crofton K.M., Howard J.L., Moser V.C., Gill M.W., Reiter L.W., Tilson H.A., MacPhail R.C. (1991).
Interlaboratory Comparison of Motor Activity Experiments: Implication for Neurotoxicological Assessments.
Neurotoxicol. Teratol.. 13. 599-609.
[31] Weingand K. Brown G. Hall R et al. (1996). Harmonisation of Animal Clinical Pathology Testing in
Toxicity and Safety Studies. Fundam. & Appl. Toxicol., 29: 198-201.
[32] EMEA (draft) document ’Non-clinical guideline on drug-induced hepatotoxicity’ (Doc. Ref.
EMEA/CHMP/SWP/a50115’2006)
[33] Crissman JW. Goodman DG, Hildebrandt PK et al. (2004). Best Practices Guideline:
Toxicological Histopathology. Toxicologic Pathology 32, 126-131.
11